TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Recurrent Vascular Events and Neurological Worsening Through Intensive Organized Case-Management (PREVENTION) Trial
Brief Summary: People who have had a stroke or transient ischemic attack (TIA or "mini-stroke") are at high risk of having another stroke or a heart attack. Conditions like high blood pressure and high cholesterol, along with other lifestyle behaviors (e.g., smoking), substantially increase the risk of stroke and heart disease. Aggressive treatment of these risk factors however, can significantly reduce the chance of another stroke, heart attack or death.

This study will look at different ways to optimize blood pressure and cholesterol levels and educate people about positive lifestyle changes.


Options:
A: Arm Label: Intensive pharmacist case management; Type: EXPERIMENTAL; Interventions: Drug: Antihypertensive agents and lipid lowering therapy | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DRUG; Name: Antihypertensive agents and lipid lowering therapy; Assigned to Arm(s): Intensive pharmacist case management | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care
B: Arm Label: Peer-Led Stroke Recurrence Prevention Education; Type: EXPERIMENTAL; Interventions: Behavioral: Prevent Return of Stroke | Arm Label: Usual Care (Delayed Intervention); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Prevent Return of Stroke | Intervention Type: BEHAVIORAL; Name: Prevent Return of Stroke; Assigned to Arm(s): Peer-Led Stroke Recurrence Prevention Education | Intervention Type: BEHAVIORAL; Name: Prevent Return of Stroke; Assigned to Arm(s): Usual Care (Delayed Intervention)
C: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
D: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Recurrent Vascular Events and Neurological Worsening Through Intensive Organized Case-Management (PREVENTION) Trial
Brief Summary: People who have had a stroke or transient ischemic attack (TIA or "mini-stroke") are at high risk of having another stroke or a heart attack. Conditions like high blood pressure and high cholesterol, along with other lifestyle behaviors (e.g., smoking), substantially increase the risk of stroke and heart disease. Aggressive treatment of these risk factors however, can significantly reduce the chance of another stroke, heart attack or death.

This study will look at different ways to optimize blood pressure and cholesterol levels and educate people about positive lifestyle changes.


Options:
A: Arm Label: Insulin glargine; Type: OTHER; Interventions: Drug: Insulin glargine | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): Insulin glargine
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Other: Case Management | Arm Label: Case Management; Type: EXPERIMENTAL; Interventions: Other: Case Management | Intervention Type: OTHER; Name: Case Management; Assigned to Arm(s): Case Management, Usual Care
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home Blood Pressure Monitoring Group; Type: EXPERIMENTAL; Interventions: Behavioral: Home Blood Pressure Monitoring | Intervention Type: BEHAVIORAL; Name: Home Blood Pressure Monitoring; Assigned to Arm(s): Home Blood Pressure Monitoring Group
D: Arm Label: Intensive pharmacist case management; Type: EXPERIMENTAL; Interventions: Drug: Antihypertensive agents and lipid lowering therapy | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DRUG; Name: Antihypertensive agents and lipid lowering therapy; Assigned to Arm(s): Intensive pharmacist case management | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting.
Brief Summary: Despite different pharmacological properties, the scientific evidence is inconclusive regarding which of the first-line second generation antipsychotics (SGAs) should be preferred for the individual patient suffering from psychosis. The limitations of the evidence base may be related to the highly selected samples, short duration, and rigid experimental designs of most randomized clinical trials of efficacy. Moreover a high proportion of the clinical trials are drug company sponsored which could introduce funding bias. The purpose of this non-commercially funded study is to investigate whether effectiveness differences exist among the first-line SGAs olanzapine, quetiapine, risperidone, and ziprasidone when the drugs are used in a representative clinical setting. Eligible patients are those admitted to hospital for acute psychosis and candidates for oral antipsychotic treatment. The investigators hypothesise that in the naturalistic setting of every-day clinical practice and in a diverse sample representative of most patients admitted for symptoms of acute psychosis, differential effectiveness among the SGAs could be disclosed when the patients are followed for up to 2 years. This could deliver valuable information regarding which SGA should be the starting antipsychotic drug in order to facilitate the most beneficial outcome.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: quetiapine, risperidone | Intervention Type: DRUG; Name: quetiapine, risperidone; Assigned to Arm(s): 1
B: Arm Label: Risperidone Long Acting; Type: EXPERIMENTAL; Interventions: Drug: Risperidone Long Acting | Arm Label: Oral Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral risperidone | Intervention Type: DRUG; Name: Risperidone Long Acting; Assigned to Arm(s): Risperidone Long Acting | Intervention Type: DRUG; Name: oral risperidone; Assigned to Arm(s): Oral Risperidone
C: Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A
D: Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Quetiapine, Drug: Ziprasidone | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Risperidone, Drug: Ziprasidone | Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Arm Label: Ziprasidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Quetiapine | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting.
Brief Summary: Despite different pharmacological properties, the scientific evidence is inconclusive regarding which of the first-line second generation antipsychotics (SGAs) should be preferred for the individual patient suffering from psychosis. The limitations of the evidence base may be related to the highly selected samples, short duration, and rigid experimental designs of most randomized clinical trials of efficacy. Moreover a high proportion of the clinical trials are drug company sponsored which could introduce funding bias. The purpose of this non-commercially funded study is to investigate whether effectiveness differences exist among the first-line SGAs olanzapine, quetiapine, risperidone, and ziprasidone when the drugs are used in a representative clinical setting. Eligible patients are those admitted to hospital for acute psychosis and candidates for oral antipsychotic treatment. The investigators hypothesise that in the naturalistic setting of every-day clinical practice and in a diverse sample representative of most patients admitted for symptoms of acute psychosis, differential effectiveness among the SGAs could be disclosed when the patients are followed for up to 2 years. This could deliver valuable information regarding which SGA should be the starting antipsychotic drug in order to facilitate the most beneficial outcome.


Options:
A: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Ziprasidone | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): A1
B: Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ziprasidone; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A
D: Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Quetiapine, Drug: Ziprasidone | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Risperidone, Drug: Ziprasidone | Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Arm Label: Ziprasidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Ziprasidone | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Quetiapine | Intervention Type: DRUG; Name: Ziprasidone; Assigned to Arm(s): Olanzapine, Quetiapine, Risperidone, Ziprasidone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Growth Hormone Treatment of Severe Fibromyalgia Syndrome Associated With Functional Failure of Somatotropic Axis. A Multicentre, Randomized, Double-blind, Placebo-controlled Study.
Brief Summary: The purpose of this study is to evaluate the efficacy of recombinant human growth hormone (r-hGH) treatment in severe fibromyalgia subjects with growth axis dysfunction.


Options:
A: Arm Label: Saizen®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Saizen® | Arm Label: Placebo + Saizen®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo and Saizen® | Intervention Type: DRUG; Name: Saizen®; Assigned to Arm(s): Saizen® | Intervention Type: DRUG; Name: Placebo and Saizen®; Assigned to Arm(s): Placebo + Saizen®
B: Intervention Type: DRUG; Name: sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amitriptyline, fluoxetine and tramadol alone (control group); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Study of C-reactive Protein vs. Procalcitonin to Guide Antibiotic Therapy in Patients With Severe Sepsis and Septic Shock Admitted to the Intensive Care Unit.
Brief Summary: In this study the investigators aim to test if C-reactive protein (CRP)or procalcitonin(PCT) - guided strategy allows to reduce the antibiotic use in patients wiht severe sepsis and septic shock. Therefore, the safety of this intervention will be carefully measured.


Options:
A: Arm Label: Group 1 - C-reactive protein (CRP) guided ab therapy; Type: EXPERIMENTAL; Interventions: Other: C-reactive protein guided antibiotic therapy | Arm Label: Group 2 - procalcitonin (PCT) guided ab therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Procalcitonin guided antibiotic therapy | Intervention Type: OTHER; Name: C-reactive protein guided antibiotic therapy; Assigned to Arm(s): Group 1 - C-reactive protein (CRP) guided ab therapy | Intervention Type: OTHER; Name: Procalcitonin guided antibiotic therapy; Assigned to Arm(s): Group 2 - procalcitonin (PCT) guided ab therapy
B: Arm Label: PCT; Type: EXPERIMENTAL; Interventions: Behavioral: a strategy based on PCT guided AB therapy | Arm Label: Guidelines; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: a strategy based on PCT guided AB therapy | Intervention Type: BEHAVIORAL; Name: a strategy based on PCT guided AB therapy; Assigned to Arm(s): Guidelines, PCT
C: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Study of C-reactive Protein vs. Procalcitonin to Guide Antibiotic Therapy in Patients With Severe Sepsis and Septic Shock Admitted to the Intensive Care Unit.
Brief Summary: In this study the investigators aim to test if C-reactive protein (CRP)or procalcitonin(PCT) - guided strategy allows to reduce the antibiotic use in patients wiht severe sepsis and septic shock. Therefore, the safety of this intervention will be carefully measured.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1
B: Arm Label: Group 1 - C-reactive protein (CRP) guided ab therapy; Type: EXPERIMENTAL; Interventions: Other: C-reactive protein guided antibiotic therapy | Arm Label: Group 2 - procalcitonin (PCT) guided ab therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Procalcitonin guided antibiotic therapy | Intervention Type: OTHER; Name: C-reactive protein guided antibiotic therapy; Assigned to Arm(s): Group 1 - C-reactive protein (CRP) guided ab therapy | Intervention Type: OTHER; Name: Procalcitonin guided antibiotic therapy; Assigned to Arm(s): Group 2 - procalcitonin (PCT) guided ab therapy
C: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A
D: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Study of C-reactive Protein vs. Procalcitonin to Guide Antibiotic Therapy in Patients With Severe Sepsis and Septic Shock Admitted to the Intensive Care Unit.
Brief Summary: In this study the investigators aim to test if C-reactive protein (CRP)or procalcitonin(PCT) - guided strategy allows to reduce the antibiotic use in patients wiht severe sepsis and septic shock. Therefore, the safety of this intervention will be carefully measured.


Options:
A: Arm Label: Group 1 - C-reactive protein (CRP) guided ab therapy; Type: EXPERIMENTAL; Interventions: Other: C-reactive protein guided antibiotic therapy | Arm Label: Group 2 - procalcitonin (PCT) guided ab therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Procalcitonin guided antibiotic therapy | Intervention Type: OTHER; Name: C-reactive protein guided antibiotic therapy; Assigned to Arm(s): Group 1 - C-reactive protein (CRP) guided ab therapy | Intervention Type: OTHER; Name: Procalcitonin guided antibiotic therapy; Assigned to Arm(s): Group 2 - procalcitonin (PCT) guided ab therapy
B: Arm Label: PCT group; Type: EXPERIMENTAL; Interventions: Other: Procalcitonin-guided decision making | Arm Label: Standard group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Procalcitonin-guided decision making; Assigned to Arm(s): PCT group
C: Arm Label: Procalcitonin-guided group; Type: N/A; Interventions: Other: Literature search | Arm Label: Routine practice group; Type: N/A; Interventions: Other: Literature search | Intervention Type: OTHER; Name: Literature search; Assigned to Arm(s): Procalcitonin-guided group, Routine practice group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Study of Ruxolitinib Tablets Compared to Best Available Therapy in Subjects With Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis
Brief Summary: This was an open label, randomized study comparing the efficacy and safety of randomized 2:1 Ruxolitinib tablets versus best-available therapy, as selected by the investigator. The purpose was to compare the efficacy, safety and tolerability of Ruxolitinib (INC424/INCB018424) given twice daily to the best-available therapy, in subjects with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PPV-MF) or post essential thrombocythemia myelofibrosis (PET-MF).


Options:
A: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Arm Label: Best Available Therapy (BAT); Type: ACTIVE_COMPARATOR; Interventions: Drug: Best Available Therapy (BAT) | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Ruxolitinib | Intervention Type: DRUG; Name: Best Available Therapy (BAT); Assigned to Arm(s): Best Available Therapy (BAT)
B: Arm Label: Ruxolitinib 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Ruxolitinib 5 mg
C: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ruxolitinib, Drug: Placebo | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Placebo, Ruxolitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Lenalidomide + Prednisone; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide, Drug: Prednisone | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Lenalidomide + Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Lenalidomide + Prednisone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Montelukast Therapy on Respiratory Symptoms, Lung Function and Airway Responsiveness in Wheezy Very Young Children
Brief Summary: The study is designed to evaluate the efficacy of montelukast on symptom-free days in unselected group of very young children with wheeze and recurrent asthma like symptoms. The secondary aim was to evaluate the effect of montelukast on lung function, airway responsiveness, airway inflammation and use of rescue medication.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo granules | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo granules; Assigned to Arm(s): 2
B: Arm Label: montelukast; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): montelukast
C: Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: placebo; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass
Brief Summary: Randomized controlled trial of the use of glucocorticoids to improve the clinical course of neonates post-cardiopulmonary bypass (CPB).


Options:
A: Arm Label: Single dose steroid; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone (IVMP) | Arm Label: Two Dose steroid; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone (two doses IVMP) | Intervention Type: DRUG; Name: methylprednisolone (IVMP); Assigned to Arm(s): Single dose steroid | Intervention Type: DRUG; Name: methylprednisolone (two doses IVMP); Assigned to Arm(s): Two Dose steroid
B: Arm Label: Methylprednisolone Arm; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic saline | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Methylprednisolone Arm | Intervention Type: DRUG; Name: Isotonic saline; Assigned to Arm(s): Placebo Arm
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Treatment | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Hydrocortisone | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): A, B

Answer: A